A new drug that activates the immune system in the respiratory tract to fight the SARS-CoV-2 coronavirus may also be effective against the common cold virus. This is reported in an article published in the European Respiratory Journal. Briefly about the scientific work is described in the press release on MedicalXpress.
Researchers have shown that INNA-X nasal spray significantly reduces viral load and suppresses dangerous inflammation in the respiratory tract. Rhinovirus is the most common respiratory virus, the main cause of the common cold and is responsible for exacerbation of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. The effectiveness of the drug is shown on the cells of the human respiratory tract.
Scientists have studied the effect of INNA-X on the respiratory cells of patients with asthma, which have a less effective antiviral immune response, and have found that the drug is suitable for use in people in high-risk groups. The spray maintains the first line of defense against the virus, making it difficult for the infection to enter the respiratory tract.
Experts plan to start testing the tool with human participation.
